With Gilenya gener­ics loom­ing, No­var­tis’ sipon­i­mod team buffs up the MS da­ta pack­age be­ing prepped for the FDA

Re­searchers for No­var­tis $NVS turned up at the 70th Amer­i­can Acad­e­my of Neu­rol­o­gy an­nu­al meet­ing in LA Fri­day to pol­ish up their piv­otal da­ta pack­age for their would-be MS block­buster sipon­i­mod.

In the lat­est up­date on Phase III re­sults, they not­ed that while there was no ben­e­fit in mem­o­ry, pa­tients in the drug arm did get a sig­nif­i­cant boost on cog­ni­tive pro­cess­ing speed com­pared to place­bo (p=0.0004). And they have da­ta to demon­strate that there’s a sig­nif­i­cant re­duc­tion in risk of dis­ease pro­gres­sion among non-re­lapse pa­tients that grows from a sus­tained lev­el of 14%-to-20% at three months to 29%-to-33% at six months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER